Biohaven’s Migraine Empire Expands As Zavegepant Conquers Phase III
Second Drug Is Market’s First Intranasal CGRP Inhibitor
Executive Summary
The company will seek US FDA approval after intranasally administered zavegepant passes its second pivotal test in the treatment of migraine attacks, followed by ex-US approvals with partner Pfizer.
You may also be interested in...
Biohaven Gets Pfizer’s Help To Make Nurtec An Ex-US Success Story Too
As the only oral CGRP migraine therapy approved for both prevention and acute therapy, Nurtec has taken significant US market share. Biohaven will call on Pfizer’s expertise and contacts to repeat that success abroad.
AbbVie Ready To Leverage Migraine Franchise In Crowded Market
The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.
Biohaven Pursues Best-In-Class Sales With Nurtec ODT’s Migraine Prevention Approval
CEO Vlad Coric said the customizable use of Nurtec ODT to stop and prevent migraine attacks is a differentiating factor that will help it go up against big pharma competitors.